These agents have shown impressive clinical activity in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), making BTK inhibition the preferred front-line therapy. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.